Previous Close | 74.56 |
Open | 74.77 |
Bid | 73.93 x 800 |
Ask | 73.95 x 1400 |
Day's Range | 73.81 - 74.95 |
52 Week Range | 53.22 - 80.59 |
Volume | |
Avg. Volume | 11,349,591 |
Market Cap | 157.646B |
Beta (5Y Monthly) | 0.39 |
PE Ratio (TTM) | 24.53 |
EPS (TTM) | 3.01 |
Earnings Date | Oct 26, 2022 |
Forward Dividend & Yield | 2.16 (2.90%) |
Ex-Dividend Date | Jun 30, 2022 |
1y Target Est | 81.38 |
Bristol Myers is a top drugmaker that investors can count on for long-term growth and dividend income. In its most recent quarter, for the period ended June 30, the company reported revenue of $11.9 billion that rose 2% year over year. The company's continued innovation makes it a promising investment.
NEW YORK, August 17, 2022--Bristol Myers Squibb Completes Acquisition of Turning Point Therapeutics, Expanding Precision Oncology Portfolio
NEW YORK & SAN DIEGO, August 16, 2022--Bristol Myers Squibb and Turning Point Therapeutics Announce Expiration of HSR Act Waiting Period and Clearance from SEE RELEASE FOR FULL TITLE